PO-0667: Is there a relationship between 18F-FDG metabolic parameters and pre-treatment HPV status in oropharyngeal cancer?  by Miccichè, F. et al.
2nd ESTRO Forum 2013   S253 
Purpose/Objective: Nuclear EGFR has been implicated in resistance 
to both radiation and EGFR-inhibition. Src family kinases (SFKs) are 
required for translocation of EGFR to the nucleus. We investigated 
whether inhibition of SFK via dasatinib can enhance the effect of 
radiotherapy in in vivo head and neck squamous cell carcinoma 
(HNSCC) models.  
Materials and Methods: Two HNSCC xenograft models, SCCNij153 and 
SCCNij202, were treated with dasatinib, radiation or both, and effects 
on growth delay, EGFR signaling, DNA repair, hypoxia and 
proliferation were investigated. 
Results: Dasatinib and radiotherapy induced a significant growth delay 
in both HNSCC xenograft models, although to a lesser extent in 
SCCNij202. Dasatinib did not inhibit pAKT or pERK1/2, but did inhibit 
(p)DNA-PK. Moreover, dasatinib reduced radiation-induced DNA repair 
as shown by an increase of 53BP1 staining 24h after radiation. This 
effect on DNA repair was only observed in the cell compartment 
where pSFK was expressed; for SCCNij153 tumors in normoxic and 
hypoxic areas, for SCCNij202 tumors only in hypoxic areas. No 
consistent effects of dasatinib on hypoxia or proliferation were 
observed.  
Conclusions: Dasatinib enhances the effect of radiotherapy in vivo by 
inhibition of radiation-induced DNA repair and is a promising way to 
improve outcome in HNSCC patients. 
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Purpose/Objective: Induction bio-chemotherapy followed by 
intensity-modulated radiotherapy (IMRT) for advanced nasopharyngeal 
carcinoma (NPC) patients has never been studied. We report the 
treatment outcome of this new approach and the effect of plasma EBV 
DNA monitoring. 
Materials and Methods: Twenty-five patients with previously 
untreated, stage III/IV NPC received induction bio-chemotherapy 
followed by IMRT. Induction chemotherapy consists of weekly P-FL 
(cisplatin 60 mg/m2 d1, [5-fluorouracil 2500 mg/m2 + leucovorin 250 
mg/m2] d8) ± gemcitabine 1000 mg/m2 or docetaxel 50 mg/m2 d15, 
for 10-12 weeks. Cetuximab 400 mg/m2 day 1, then 250 mg/m2 were 
administered every week. IMRT 70 Gy/35fr was delivered to T1-3 
lesions and 74 Gy/37fr or 76.8 Gy/64fr to the T4 tumor. Plasma EBV 
DNA levels were measured before, during and after treatment 
regularly. 
Results: Baseline characteristics are median age=44; 
male/female=19/6; performance status ECOG 0/1=13/12; stage 
III/IV=12/13, and pathological type (WHO) IIa/IIb=12/13. All patients 
tolerated induction bio-chemotherapy very well. Grade 3 toxicity 
included leucopenia (8.0%) and skin rashes (40.0%). There was no 
grade 4 toxicity. After induction bio-chemotherapy, we obtained 
52.0% complete response rate and 48.0% partial response rate. 
Thirteen of 24 (54.2%) patients who received re-biopsy of the 
nasopharynx before IMRT were reported as no viable tumor. IMRT was 
performed smoothly with a median of 49 days (range 45-53). After a 
median follow-up of 21 months, no locoregional recurrence was 
noted. Four patients failed in distant sites. So far, all patients are 
alive. Patients with high pretreatment plasma EBV DNA and with 
persistently detectable post-IMRT plasma EBV DNA had a significantly 
higher relapse rate than those of the counterpart (40.0% vs. 0%, 
P=0.0166; and 50% vs. 5.3%, P=0.0312). 
Conclusions: Weekly cetuximab plus chemotherapy followed by IMRT 
is a highly effective protocol with very low toxicity in advanced NPC. 
Plasma EBV DNA assay can predict treatment failure.  
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Purpose/Objective: To evaluate the relation between the baseline 
Fluorine-18-Fluorodeoxyglucose (18F-FDG) positron emission tomo-
graphy–computed tomography PET–CT and human papillomavirus (HPV) 
infection in patients with advanced oropharyngeal squamous cell 
carcinoma (SCC) treated with radio-chemotherapy. 
Materials and Methods: We retrospectively analyzed patients with 
stage III or IV SCC of the oropharynx enrolled between February 2007 
and December 2010. All patients were submitted to 18F-FDGPET–CT at 
staging. FDG uptake in the primary tumor (T) and lymph nodes (N) was 
correlated with primary site and HPV status. Metabolic FDG PET 
parameters (T-SUVmax, T-SUVmean 40%, T-SUVmean 50%, T-SUVmeanmanual, 
N-SUVmax, T/N SUVmax, T volume 40%, T volume 50%,T volume manual) 
were correlated with relapse free survival (RFS) and disease specific 
survival (DSS). HPV DNA was detected by Digene Hybrid Capture 2 
(HC2). HPV E6 and E7 mRNA were detected by NucliSENS® 
EasyQ®HPVv1. RFS and DSS were plotted by the Kaplan-Meier method. 
The various FDG PET parameters were put in relation with survival 
endpoints by Cox regression analysis. 
Results: Forty-five patients studied at initial staging were analyzed. 
Twenty-seven patients had an HPV infection and 18 patients were HPV 
negative. No statistically significant differences in RFS nor DSS were 
found according to primary site,while a marked difference in DSS 
(p=0.0177 at log rank test), but not in RFS, was observed between 
HPV positive versus HPV negative cases. Conversely, HPV status did 
not significantly affect any of the FDG PET metabolic parameters 
under examination. None of the above cited PET parameters tested in 
a univariate Cox regression model showed a correlation with RFS nor 
DSS. 
Conclusions: Our results confirm the prognostic value of HPV infection 
in oropharyngeal cancer. On the other hand, in this retrospective 
study we did not find any correlation between FDG PET metabolic 
parameters and HPV status or survival. Prospective studies in larger 
series are needed to better evaluate possible correlation between HPV 
status and metabolic parameters. 
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Purpose/Objective: The tumor volume (TV) is probably the most 
important among other prognostic factors for radiotherapy (RT) of 
patients with laryngeal cancer. The purpose of the study is to 
determine how the volume of early laryngeal cancer may influence 
the outcome of RT. 
Materials and Methods: Between 2002 and 2006, 160 patients with T2 
laryngeal squamous cell carcinoma were treated with RT in Maria 
Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 
Gliwice Branch. The group consists of 129 (80.5%) men and 31(19.5%) 
women in mean age of 60 years (range 39-82 years). All of them were 
treated exclusively with RT to the median total dose of 68.4 Gy. The 
tumor was localized in glottis and supraglottis respectively in 82 (51%) 
and 78 (49%) patients. Median TV was 2.01 cm3 (range 0.11 - 21.64 
cm3). Median hemoglobin concentration before (Hb0) and after (Hb1) 
RT was 14.6 and 13.2 g/dl respectively. Median body mass and body 
mass index before (M0, BMI0) and after RT (M1, BMI1) were 27kg, 26 
kg and 75.7 kg, 75 kg respectively. Survival rates were calculated by 
the Kaplan-Meier method. Differences between survival rates were 
assessed by the log-rank statistic. The Cox proportional hazards 
method was used for multivariate analyses. 
Results: 5-year LC rate was 70%. 5-year OS rate was 63%. The median 
value of TV of locally cured patients was significantly lower than of 
those who locally failed (p=0.04). Median TV for supraglottic tumors 
was significantly higher than for glottic tumors p<0.0001. Poorly 
differentiated tumors (G2, G3) had significantly higherTV than G1 
tumors (p=0.01). There was significant negative correlation between 
TV and Hb0, Hb1, M0 and M1. TV as continuous variable significantly 
influenced LC (p=0.01) and OS (p=0.00003). Patients with TV over 2 
cm3 and those with TV over 6.7 cm3 present almost two and over three 
times higher risk of death respectively. In multivariate analysis both 
age (p=0.03) and TV (p=0.01) remained significantly related to LC. Age 
(p=0.0005), BMI0 (p=0.005) and TV (p=0.0001) remained significantly 
related to OS.  
Conclusions: TV significantly changes the prognosis of RT outcome for 
patients with early laryngeal cancer. Due to the significant relation 
with other factors, TV should be considered during the choice of 
optimal treatment for such patients. 
   
 
